申请人:ENANTA PHARM INC
公开号:WO2017015451A1
公开(公告)日:2017-01-26
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
本发明揭示了化合物的结构式(I),或其药用可接受的盐、酯或前药:X-A1-Y-A2-Z-L-R(I),这些化合物能够抑制由乙型肝炎病毒(HBV)编码的蛋白质,或干扰乙型肝炎病毒的生命周期功能,同时也可作为抗病毒药物使用。本发明还涉及包含上述化合物的药物组合物,用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗HBV感染的方法。